Manufacturing again targeted in Arena cost cutting


Arena, developer of obesity med Belviq, knows something about slimming down. For the second time in 9 months, the San Diego-based drug company will slim itself, cutting jobs and costs, with manufacturing again taking a hit.

Arena ($ARNA) said last week it is cutting its workforce by 73% as it pivots its focus to its clinical-stage pipeline and as Belviq sales fail to develop as it had hoped. It will eliminate about 100 jobs in the process. The job cuts will hit manufacturing, as well as research and general and administrative functions. The company expects it will cut annual costs by between $23 million and $25 million. It was short on details but said that it “plans to implement additional cost control measures to further reduce its expenditures, including reductions at its Swiss manufacturing facility.”

The reorganization is no surprise given the difficulties that Belviq has faced since launching in 2013. Despite a hefty investment from marketing partner Eisai--a DTC campaign and a rep army hundreds strong--the med has not taken off. In last year’s Q4, Arena netted just $3.9 million in royalties on just $8 million in Eisai sales--a topline haul for the Japanese drugmaker that declined for the fourth straight quarter.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

In October, Arena had made similar cuts. At that time, it said it would reduce its U.S. workforce by 35%, about 80 employees, in an effort to realize about $11 million in annual costs. In October, it also indicated it would do "additional cost-cutting, including at its Swiss manufacturing facility."

- here’s the release

Related Articles: 
Arena chops 100-plus jobs as it shifts its priorities from struggling Belviq 
Elsai slashes Belviq sales force as Arena marketing deal goes sour 
Investors cheer as Arena forces out CEO and cofounder


Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.